These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 33127831)
1. Prognostic value of van Ipenburg JA; Naus NC; Dubbink HJ; van Ginderdeuren R; Missotten GS; Paridaens D; Verdijk RM Br J Ophthalmol; 2021 Oct; 105(10):1454-1461. PubMed ID: 33127831 [TBL] [Abstract][Full Text] [Related]
2. Conjunctival malignant melanoma in Denmark: epidemiology, treatment and prognosis with special emphasis on tumorigenesis and genetic profile. Larsen AC Acta Ophthalmol; 2016 May; 94 Thesis 1():1-27. PubMed ID: 27192168 [TBL] [Abstract][Full Text] [Related]
3. Impact of BRAF V600E and TERT Promoter Mutations on Response to Therapy in Papillary Thyroid Cancer. Trybek T; Walczyk A; Gąsior-Perczak D; Pałyga I; Mikina E; Kowalik A; Hińcza K; Kopczyński J; Chrapek M; Góźdź S; Kowalska A Endocrinology; 2019 Oct; 160(10):2328-2338. PubMed ID: 31305897 [TBL] [Abstract][Full Text] [Related]
4. Effects of Coexistent BRAF Moon S; Song YS; Kim YA; Lim JA; Cho SW; Moon JH; Hahn S; Park DJ; Park YJ Thyroid; 2017 May; 27(5):651-660. PubMed ID: 28181854 [TBL] [Abstract][Full Text] [Related]
5. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. Xing M; Liu R; Liu X; Murugan AK; Zhu G; Zeiger MA; Pai S; Bishop J J Clin Oncol; 2014 Sep; 32(25):2718-26. PubMed ID: 25024077 [TBL] [Abstract][Full Text] [Related]
6. Coexistence of TERT promoter and BRAF mutations in cutaneous melanoma is associated with more clinicopathological features of aggressiveness. Macerola E; Loggini B; Giannini R; Garavello G; Giordano M; Proietti A; Niccoli C; Basolo F; Fontanini G Virchows Arch; 2015 Aug; 467(2):177-84. PubMed ID: 26055532 [TBL] [Abstract][Full Text] [Related]
7. Molecular Genetics of Conjunctival Melanoma and Prognostic Value of van Poppelen NM; van Ipenburg JA; van den Bosch Q; Vaarwater J; Brands T; Eussen B; Magielsen F; Dubbink HJ; Paridaens D; Brosens E; Naus N; de Klein A; Kiliç E; Verdijk RM Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071371 [TBL] [Abstract][Full Text] [Related]
8. BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patients. Jin L; Chen E; Dong S; Cai Y; Zhang X; Zhou Y; Zeng R; Yang F; Pan C; Liu Y; Wu W; Xing M; Zhang X; Wang O Oncotarget; 2016 Apr; 7(14):18346-55. PubMed ID: 26943032 [TBL] [Abstract][Full Text] [Related]
9. In Japanese patients with papillary thyroid carcinoma, TERT promoter mutation is associated with poor prognosis, in contrast to BRAF Nasirden A; Saito T; Fukumura Y; Hara K; Akaike K; Kurisaki-Arakawa A; Asahina M; Yamashita A; Tomomasa R; Hayashi T; Arakawa A; Yao T Virchows Arch; 2016 Dec; 469(6):687-696. PubMed ID: 27718012 [TBL] [Abstract][Full Text] [Related]
10. [ Yang T; Chen C; Pan NF; Sun LY; Jiang XL; Li JN; Tang Y; Jiang Y Sichuan Da Xue Xue Bao Yi Xue Ban; 2019 Dec; 50(6):919-924. PubMed ID: 31880125 [TBL] [Abstract][Full Text] [Related]
11. Classic Architecture with Multicentricity and Local Recurrence, and Absence of TERT Promoter Mutations are Correlates of BRAF (V600E) Harboring Pediatric Papillary Thyroid Carcinomas. Onder S; Ozturk Sari S; Yegen G; Sormaz IC; Yilmaz I; Poyrazoglu S; Sanlı Y; Giles Senyurek Y; Kapran Y; Mete O Endocr Pathol; 2016 Jun; 27(2):153-61. PubMed ID: 26951110 [TBL] [Abstract][Full Text] [Related]
12. Presence of TERT ± BRAF V600E mutation is not a risk factor for the clinical management of patients with papillary thyroid microcarcinoma. Lee J; Ha EJ; Roh J; Kim HK Surgery; 2021 Sep; 170(3):743-747. PubMed ID: 33952391 [TBL] [Abstract][Full Text] [Related]
13. Effect of BRAF Mu ZZ; Zhang YQ; Sun D; Lu T; Lin YS Endocr Pract; 2022 Mar; 28(3):265-270. PubMed ID: 34890787 [TBL] [Abstract][Full Text] [Related]
14. Relevance and clinicopathologic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest China. Huang M; Yan C; Xiao J; Wang T; Ling R Diagn Pathol; 2019 Jul; 14(1):74. PubMed ID: 31300059 [TBL] [Abstract][Full Text] [Related]
15. Arms-qPCR Improves Detection Sensitivity of Earlier Diagnosis of Papillary Thyroid Cancers With Worse Prognosis Determined by Coexisting BRAF V600E and Tert Promoter Mutations. Yu PC; Tan LC; Zhu XL; Shi X; Chernikov R; Semenov A; Zhang L; Ma B; Wang Y; Zhou XY; Ji QH; Wei WJ; Wang YL Endocr Pract; 2021 Jul; 27(7):698-705. PubMed ID: 33515759 [TBL] [Abstract][Full Text] [Related]
16. Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients. Song YS; Lim JA; Choi H; Won JK; Moon JH; Cho SW; Lee KE; Park YJ; Yi KH; Park DJ; Seo JS Cancer; 2016 May; 122(9):1370-9. PubMed ID: 26969876 [TBL] [Abstract][Full Text] [Related]
17. TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours. Griewank KG; Murali R; Schilling B; Scholz S; Sucker A; Song M; Süsskind D; Grabellus F; Zimmer L; Hillen U; Steuhl KP; Schadendorf D; Westekemper H; Zeschnigk M Br J Cancer; 2013 Jul; 109(2):497-501. PubMed ID: 23799844 [TBL] [Abstract][Full Text] [Related]
18. TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer. Liu X; Qu S; Liu R; Sheng C; Shi X; Zhu G; Murugan AK; Guan H; Yu H; Wang Y; Sun H; Shan Z; Teng W; Xing M J Clin Endocrinol Metab; 2014 Jun; 99(6):E1130-6. PubMed ID: 24617711 [TBL] [Abstract][Full Text] [Related]
20. Bai X; Kong Y; Chi Z; Sheng X; Cui C; Wang X; Mao L; Tang B; Li S; Lian B; Yan X; Zhou L; Dai J; Guo J; Si L Clin Cancer Res; 2017 Oct; 23(20):6120-6127. PubMed ID: 28720667 [No Abstract] [Full Text] [Related] [Next] [New Search]